Combination drug therapy for laryngopharyngeal reflex
DOI:
https://doi.org/10.18203/issn.2454-5929.ijohns20201693Keywords:
Laryngopharyngeal reflux, Gastroesophageal reflux disease, Reflux symptom index, Reflux finding score, Proton-pump inhibitors, H2 receptor antagonistsAbstract
Background: We sought to evaluate the combination of high-dose prebreakfast proton pump inhibitors (PPIs) (40 mg pantoprazole) and a bedtime high-dose ranitidine (300 mg) dosing as a surrogate and rational regimen for LPR.
Methods: 60 subjects that presented to ENT and HNS OPD with symptoms of laryngopharyngeal reflux (LPR) were prospectively evaluated and underwent a comprehensive otolaryngological examination. All subjects were treated sequentially and outcomes recorded using reflux finding score (RFS) and reflux symptom index (RSI).
Results: The mean age of the cohort was 35±06.51 (age range, 8-55). Mean RSI of all patients was 24.8 before treatment with combination of PPIs and H2 receptor antagonists. Significant change in RSI were observed after the first 8 weeks of therapy and no further significant changes were observed over the next 16 weeks. Mean RFS of the patients was 12 before starting the treatment and there was a significant response in mean RFS at 16 weeks of therapy.
Conclusions: A surrogate high-dose prebreakfast PPI (40 mg pantoprazole) and a bedtime high-dose ranitidine (300 mg) dosing regimen is effective in improving RSI and RFS in majority of cases who present with LPR.
References
Serag EHB. Time trends of gastroesophageal reflux disease: a systematic review. Clin Gastroenterol Hepatol. 2007;5:17-26.
Altman KW, Stephens RM, Lyttle CS, Weiss KB. Changing impact of gastroesophageal reflux in medical and otolaryngology practice. Laryngoscope. 2005;115:1145-53.
Koufman JA. Low-acid diet for recalcitrant laryngopharyngeal reflux: therapeutic benefits and their implications. Ann Otol Rhinol Laryngol. 2011;120:281-7.
Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst. 2005;97:142-6.
Koufman JA, Johnston N. Potential benefits of pH 8.8 alkaline drinking water as an adjunct in the treatment of reflux disease. Ann Otol Rhinol Laryngol. 2012;121:431-4.
Koufman JA. The otolaryngologic manifestations of gastroesophageal reflux disease (GERD): a clinical investigation of 225 patients using ambulatory 24-hour pH monitoring and an experimental investigation of the role of acid and pepsin in the development laryngeal injury. Laryngoscope. 1991;101(52):1-78.
Koufman JA, Amin MR, Panetti M. Prevalence of reflux in 113 consecutive patients with laryngeal and voice disorders. Otolaryngol Head Neck Surg. 2000;123:385-8.
Modlin IM, Moss SF, Kidd M, Lye KD. Gastroesophageal reflux disease: then and now. J Clin Gastroenterol. 2004;38(5):390-402.
Knol KEC. Otolaryngologic manifestations of gastro-oesophageal reflux disease. Scand J Gastroenterol Suppl. 1998;225:24-8.
Hawkins BL. Laryngopharyngeal reflux: a modern day “great masquerader”. J Ky Med Assoc. 1997;95(9):379-85.
Ford CN. Evaluation and management of laryngopharyngeal reflux. JAMA. 2005;294:1534-40.
Belafsky PC, Postma GN, Koufman JA. Validity and reliability of the reflux symptom index (RSI). J Voice. 2002;16: 274-7.
Belfasky PC, Postma GN. The validity and reliability of reflux finding score. The laryngoscope. 2001;111:1313-7.
Lechien JR, Schindler A, Marrez DLG, Hamdan AL, Karkos PD, Harmegnies B, et al. Instruments evaluating the clinical findings of laryngopharyngeal reflux: A systematic review. Laryngoscope. 2018.
Branski RC, Bhattacharyya N, Shapiro J. The reliability of the assessment of endoscopic laryngeal findings associated with laryngopharyngeal reflux disease. Laryngoscope. 2002;112:1019-24.
Koufman JA, Aviv JE, Casiano RR, Shaw GY. Laryngopharyngeal reflux: position statement of the committee on speech, voice, and swallowing disorders of the American Academy of Otolaryngology - Head and Neck Surgery. Otolaryngol Head Neck Surg. 2002;127:32-5.
Leite LP, Johnston BT, Just RJ, Castell DO. Persistent acid secretion during omeprazole therapy: a study of gastric acid profiles in patients demonstrating failure of omeprazole therapy. Am J Gastroenterol. 1996;91:1527-31.
Berardi RR. A critical evaluation of proton pump inhibitors in the treatment of gastroesophageal reflux disease. Am J Manag Care. 2000;6:491-505.
Carroll TL, Werner A, Nahikian K, Dezube A, Roth DF. Rethinking the laryngopharyngeal reflux treatment algorithm: Evaluating an alternate empiric dosing regimen and considering up-front, pH-impedance, and manometry testing to minimize cost in treating suspect laryngopharyngeal reflux disease. Laryngoscope. 2017;127(6):1-13.
Park W, Hicks DM, Khandwala F, Richter JE, Abelson TI, Milstein C, et al. Laryngopharyngeal reflux: prospective cohort study evaluating optimal dose of proton-pump inhibitor therapy and pretherapy predictors of response. Laryngoscope. 2005;115:1230-8.
Yang J, Dehom S, Sanders S, Murry T, Krishna P, Crawley BK. Treating laryngopharyngeal reflux: Evaluation of an anti-reflux program with comparison to medications. Am J Otolaryngol. 2018;39:50-5.
Suzuki M, Yokota M, Matsumoto T, Nakayama M, Takemura M, Kanemitsu Y, et al. Proton Pump Inhibitor Ameliorates Taste Disturbance among Patients with Laryngopharyngeal Reflux: A Randomized Controlled Study. Tohoku J Exp Med. 2019;247:19-25.
Axford SE, Sharp N, Ross PE. Cell biology of laryngeal epithelial defenses in health and disease: preliminary studies. Ann Otol Rhinol Laryngol. 2001;110:1099-108.
Hogan W, Shaker R. Medical treatment of supraesophageal complications of gastroesophageal reflux disease. Am J Med. 2001;111(l-8A):197-201.
Xue S, Katz P, Banerjee P, Tutuian R, Castell D. Bedtime H2 blockers improve nocturnal gastric acid control in GERD patients on proton pump inhibitors. Aliment Pharmacol Ther. 2001;15:1351-6.
Scarpignato C, Pelosini I, Mario DF. Acid suppression therapy: where do we go from here. Dig Dis. 2006;24:11-4.
Peghini PL, Katz PO, Bracy NA. Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. American J Gastroenterology. 1998;93:763-67.
Reimer C. Safety of long-term PPI therapy. Best Pract Res Clin Gastroenterol. 2013;27:443-54.
Fass R. Alternative therapeutic approaches to chronic proton pump inhibitor treatment. Clin Gastroenterol Hepatol. 2012;10:338-45.
Guo H, Ma H, Wang J. Proton pump inhibitor therapy for the treatment of laryngopharyngeal reflux: A meta-analysis of randomized controlled trials. J Clin Gastroenterol. 2016;50:295-300.
Issing WJ, Karkos PD, Perreas K, Folwaczny C, Reichel O. Dual-probe 24 hours ambulatory pH monitoring for diagnosis of laryngopharyngeal reflux. J Laryngol Otol. 2004;118:845-8.
Bilgen C, Ogut F, Dinc KH, Kirazli T, Bor S. The comparison of an empiric proton pump inhibitor trial vs 24 hours double-probe Ph monitoring in laryngopharyngeal reflux. J Laryngol Otol. 2003;117:386-90.
Mesallam TA, Stemple JC, Sobeih TM, Elluru RG. Reflux symptom index versus reflux finding score. Ann Otol Rhinol Laryngol. 2007;116:436-40.
Toros SZ, Toros AB, Yuksel OD, Ozel L, Akkaynak C, Naiboglu B, et al. Association of laryngopharyngeal manifestations and gastroesophageal reflux. Eur Arch Otorhinolaryngol. 2009;266:403-9.
Patigaroo SA, Hashmi SF, Hasan SA, Ajmal MR, Mehfooz N. Clinical manifestations and role of proton pump inhibitors in the management of laryngopharyngeal reflux. Indian J Otolaryngol Head Neck Surg. 2011;63:182-9.
The Gallup Organization. The 2000 study of consumers’ use of stomach relief products. Princeton, NJ: The Gallup Organization; 2000.
Koufman J, Sataloff RT, Toohill R. Laryngopharyngeal reflux: consensus conference report. J Voice. 1996;10(3):215-6.
